Open AccessAntiviral therapy of hepatitis C with 1 genotype after liver transplantation
Author(s) -
О. М. Цирульникова,
Д. В. Умрик
Publication year - 2018
Publication title -
vestnik transplantologii i iskusstvennyh organov
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 5
eISSN - 2412-6160
pISSN - 1995-1191
DOI - 10.15825/1995-1191-2018-3-105-115
Subject(s) - liver transplantation , medicine , genotype , transplantation , hepatitis c virus , decompensation , liver disease , hepatitis c , antiviral therapy , immunology , virology , virus , chronic hepatitis , biology , biochemistry , gene
Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in all patients with persistent replication of the virus. Against the background of the necessary immunosuppressive therapy, the progression of the disease accelerates, leading to rapid decompensation of the liver. Antiviral therapy significantly improves the results of transplantation, but the use of standard interferon-based regimens is associated with low efficacy (no more than 30% for the most common 1 genotype of the virus) and poor tolerance. The article describes new interferon- free oral regimens used to treat the recurrence of HCV infection of 1 genotype.